<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765306</url>
  </required_header>
  <id_info>
    <org_study_id>21-004</org_study_id>
    <nct_id>NCT04765306</nct_id>
  </id_info>
  <brief_title>Fascial Closure Technique After Gynecologic Laparoscopic Surgery and Postoperative Pain</brief_title>
  <official_title>Fascial Closure Technique After Gynecologic Laparoscopic Surgery and Postoperative Pain: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jessica G Putman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study aims to determine postoperative pain outcomes when comparing port site &gt; 10 mm&#xD;
      fascial closure with traditional direct closure versus use of laparoscopic fascial closure&#xD;
      device in patients undergoing minimally invasive gynecologic surgery via laparoscopic or&#xD;
      robotic techniques. Pain outcomes will be measured using the visual analog scale.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>This will be a prospective, singled-blinded, randomized controlled study. Eligible patients who provide consent will be randomized into one of two arms either undergoing fascial closure with a fascial closure device or traditional direct closure on the day of surgery. Every patient will have equal probability of being assigned to either study arm. The patients will be blinded to which study arm they have been assigned to, but providers will be aware due to the nature of study topic.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain scores via Visual Analog Scale</measure>
    <time_frame>Through 2 weeks postoperatively</time_frame>
    <description>A 20 mm difference in VAS score and a 2-unit difference on a 10-point pain scale have been described as a clinically significant difference between treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of narcotics consumed in postoperative period</measure>
    <time_frame>Through 2 weeks postoperatively</time_frame>
    <description>Number of tablets of narcotics consumed in postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Through study completion, up to 6 months</time_frame>
    <description>Length of hospital stay in days from day of surgery until discharge home</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication</measure>
    <time_frame>Through 6 weeks postoperatively</time_frame>
    <description>Postoperative incisional infection, postoperative incisional hernia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fascial closure operating time</measure>
    <time_frame>Duration of fascial closure operating time</time_frame>
    <description>Timing of fascial closure will start when the surgeon or surgical assistant reports s/he is beginning the fascial closure and stop after the suture is cut after tying.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Traditional Direct Fascial Closure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed under traditional direct visualization without laparoscopic guidance using a single interrupted suture of 0-vicryl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fascial Closure Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed using direct laparscopic visualization with the Carter-Thomason fascial closure device with a single interrupted suture of 0-vicryl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Traditional Direct Fascial Closure</intervention_name>
    <description>Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.</description>
    <arm_group_label>Traditional Direct Fascial Closure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fascial Closure Device</intervention_name>
    <description>Fascial closure using a fascial closure device under direct laparoscopic guidance.</description>
    <arm_group_label>Fascial Closure Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 or older.&#xD;
&#xD;
          -  Any patient undergoing laparoscopic gynecologic surgery with one left upper quadrant&#xD;
             port site &gt; 10 mm via either robotic or traditional laparoscopic techniques for any&#xD;
             indication including abnormal bleeding, pelvic pain, gynecologic cancer, uterine&#xD;
             fibroids, etc. Procedures performed will include but not be limited to hysterectomy,&#xD;
             bilateral or unilateral salpingoophorectomy, ovarian cystectomy, and pelvic floor&#xD;
             support procedures.&#xD;
&#xD;
          -  Patients willing and able to give informed consent.&#xD;
&#xD;
          -  Patients capable and willing to return for follow up and complete pain diaries.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to return for follow up.&#xD;
&#xD;
          -  Patients undergoing laparoscopic surgery that requires conversion to laparotomy.&#xD;
&#xD;
          -  Patients undergoing laparoscopic surgery that does not require a port site &gt;10 mm.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Boren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee College of Medicine Gynecology Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica G Putman, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Tennessee Chattanooga Minimally Invasive Gynecologic Surgery Fellow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica G Putman, MD</last_name>
    <phone>(423) 778-2531</phone>
    <email>jessica.putman@erlanger.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Todd Boren, MD</last_name>
    <phone>(423) 266-3636</phone>
    <email>todd.boren@erlanger.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erlanger Baroness Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica G Putman, MD</last_name>
      <phone>423-778-2531</phone>
      <email>jessica.putman@erlanger.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Tennessee</investigator_affiliation>
    <investigator_full_name>Jessica G Putman</investigator_full_name>
    <investigator_title>Fellow Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

